Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress

Scott M. Thompson, Matthew R. Callstrom, Danielle E. Jondal, Kim A. Butters, Bruce E. Knudsen, Jill L. Anderson, Karen R. Lien, Shari L. Sutor, Ju-Seog Lee, Snorri S. Thorgeirsson, Joseph P. Grande, Lewis R. Roberts, David A. Woodrum

1 Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN, United States of America
2 Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, United States of America
3 Genomics Research Center, Mayo Clinic College of Medicine, Rochester, MN, United States of America
4 Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States of America
5 Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
6 Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, United States of America

Abstract

Thermal ablative therapies are important treatment options in the multidisciplinary care of patients with hepatocellular carcinoma (HCC), but lesions larger than 2–3 cm are plagued with high local recurrence rates and overall survival of these patients remains poor. Currently no adjuvant therapies exist to prevent local HCC recurrence in patients undergoing thermal ablation. The molecular mechanisms mediating HCC resistance to thermal ablation induced heat stress and local recurrence remain unclear. Here we demonstrate that HCC cells with a poor prognostic hepatic stem cell subtype (Subtype HS) are more resistant to heat stress than HCC cells with a better prognostic hepatocyte subtype (Subtype HC). Moreover, sublethal heat stress rapidly induces phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dependent-protein kinase B (AKT) survival signaling in HCC cells. Conversely, inhibition of PI3K/mTORC2-dependent AKT phosphorylation or direct inhibition of AKT function both enhance HCC cell killing and decrease HCC cell survival to sublethal heat stress in both poor and better prognostic HCC subtypes while mTORC1-inhibition has no impact. Finally, we showed that AKT isoforms 1, 2 and 3 are differentially upregulated in primary human HCCs and that overexpression of AKT correlates with worse tumor biology and pathologic features (AKT3) and prognosis (AKT1). Together these findings define a novel molecular mechanism whereby heat stress induces PI3K/mTORC2-dependent AKT survival signaling in HCC cells and provide a mechanistic explanation for why HCC cells are more resistant to thermal ablation induced heat stress in vivo.
rationale for adjuvant AKT inhibition in combination with thermal ablation as a strategy to enhance HCC cell killing and prevent local recurrence, particularly at the ablation margin.

Introduction

Hepatocellular carcinoma (HCC) is a deadly, increasingly common disease for which better treatments are needed [1–5]. Image-guided percutaneous thermal ablative therapies have greatly expanded treatment options for patients with early-stage HCC, achieving short-term outcomes similar to surgery with less morbidity [6–8]. However, as tumor size increases, thermal ablation of HCC is plagued by high local recurrence and intrahepatic tumor progression rates (up to 75% at 5 years), particularly for tumors beyond 2-3cm in size. Additionally, overall survival of these patients remains poor [6–14]. Of concern, there is evidence for rapid, aggressive intrasegmental HCC recurrence following thermal ablation and currently no adjuvant therapies exist to help prevent recurrence [2, 13–18]. The ablation margin is the most common site for HCC local tumor recurrence, suggesting incomplete treatment resulting from sublethal heat stress or increase tumoral resistance [19–21].

Coagulation necrosis has been considered the primary mechanism of cell death from thermal ablation. However, given the wide variation in temperatures seen at the ablation margin in experimental studies, uniform achievement of at least 50°C throughout the tumor volume is unlikely and some regions receive a lower than desired thermal dose [22, 23]. Consequently, rapid coagulation necrosis of the entire tumor volume may not be achieved and the injured HCC cells may or may not progress to irreversible cell injury depending on the balance between pro-death versus pro-survival mechanisms. More recent studies have demonstrated that both regulated and non-regulated cell death mechanisms mediate heat stress-induced HCC cell killing in a thermal-dose dependent manner and that the mechanisms vary between hepatocytes and different HCC cell lines [24]. Moreover, apoptosis is a significant mechanism of cell death at the HCC tumor ablation margin [24].

Unfortunately, the clinical use of thermal ablation for HCC has outpaced the understanding of the basic molecular mechanisms mediating HCC-specific response to heat stress, particularly at the ablation margin where tumor recurrence remains a challenging problem [25–27]. Application of modern genomics and molecular biology techniques has showed that HCC is a heterogeneous malignancy comprised of different molecular prognostic subtypes and driven by diverse oncogenic signaling pathways [28–31]. However, the impact of the biological heterogeneity of HCC on therapeutic response to heat stress remains unknown. As such, fundamental basic and translational questions remain unanswered regarding the impact of tumor specific HCC biology on mechanisms of cell survival and alterations in oncogenic signaling in response to heat stress. Consequently, there remains a critical need to delineate molecular mechanisms mediating HCC local recurrence, particularly at the ablation margin, in order to identify therapeutic targets and develop adjuvant therapeutic strategies for enhancing thermal ablation-induced HCC cell killing.

The aims of the present study were three-fold: first, to characterize the molecular prognostic subtype of two phenotypically distinct HCC cell lines used for testing thermal ablation hypotheses and determine their thermal sensitivity using clinically relevant experimental heat stress conditions; second, to identify molecular mechanisms that promote HCC cell survival to heat stress as potential candidate adjuvant therapeutic targets, with particular attention to the PI3K-AKT-mTOR pathway; and third, to investigate the biologic and prognostic significance of candidate pathways to human HCC. The experiments herein provide evidence that sublethal
heat stress induced PI3K/mTORC2-dependant AKT signaling is a central mediator of HCC cell survival to thermal ablation induced heat stress in diverse molecular prognostic subtypes of HCC, thereby providing a mechanistic basis for adjuvant AKT inhibition as a therapeutic strategy to enhance thermal ablation induced HCC cell killing and prevent local recurrence, particularly at the ablation margin.

**Materials and Methods**

**Ethics Statement**

The microarray gene expression analysis of human HCCs reported in this study was approved by the Institutional Review Boards (IRB) of the Mayo Clinic, the Cancer Institute of the Chinese Academy of Medical Sciences, the University of Leuven and the US National Cancer Institute. Data from this patient population have been previously published [29, 32–35]. Deidentified anonymized samples were either from patients who had provided verbal or written informed consent or were surgical waste tissues from deceased patients, which were used with IRB approval. Written informed consent from a next of kin was not obtained in the case of deceased patients and the deceased patients did not constitute a vulnerable population. Verbal consent was the standard requirement of the Mayo Clinic Institutional Review Board at the time the Mayo Hepatobiliary Neoplasia Biorepository was initiated in 2001. Verbal consent was obtained from patients and documented in the patient medical record as instructed and approved by the Mayo Clinic IRB from 2001 to 2003. Beginning in 2003, the Mayo Clinic IRB required written informed consent and this was obtained and the signed consent form was scanned into each patient's electronic medical record.

**Materials**

**Cell Lines.** Clone9, N1S1, Hep3B, HepG2, PLC/PRF/5, SNU-387, SNU-423, SNU-449, SNU-475 (ATCC, Manassas, VA), AS30D (DSMZ, Braunschweig, Germany) and HuH-7 (JCRB Cell Bank, Japan) cell lines were cultured according to supplier recommendations.

**Inhibitors.** NVP-BEZ235, selumetinib (AZD6244), MK-2206 and rapamycin were purchased from Selleck Chemicals (Houston, TX); LY294002 was from Cell Signaling Technology (Danvers, MA).

**Antibodies.** Antiphospho-Ser^{173}AKT (#4060), antiphospho-Thr^{308}AKT (#2965), total AKT (#4691), AKT1 (#2938), AKT2 (#2964), AKT3 (#8018), antiphospho-Ser^{146}BAD (#4366), antiphospho-Ser^{9}GSK3B (#5558), antiphospho-Thr^{24}FoxO1/Thr^{32}FoxO3 (#9464), antiphospho-Ser^{2448}mTOR (#5536), antiphospho-Ser^{2481}mTOR (#2974), antiphospho-Thr^{202/Tyr^{204}}p44/42 MAPK (Erk1/2) (#9101; #4370), total p44/42 MAPK (Erk1/2) (#9102) and cleaved caspase-3 (#9664) antibodies were purchased from Cell Signaling Technology (Danvers, MA); Anti-Beta Actin antibody (sc-1615) was purchased from Santa Cruz Biotechnology (Dallas, TX). Peroxidase-labeled affinity purified anti-rabbit IgG (074–1506), anti-mouse IgG (074–1806), anti-mouse IgM (074–1803) and anti-goat IgG (14-13-06) antibodies were purchased from KPL (Gaithersburg, MD).

**Methods**

**Whole Transcriptome Gene Expression Analysis.** Clone9, N1S1 and AS30D cells were rinsed in 1xPBS, pelleted and snap frozen in liquid N\(_2\) (N = 4 biological replicates per cell line). Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA) per manufacturer protocol. RNA integrity was assessed using Agilent 2100 Bioanalyzer. All samples were processed using microarray technology with the Rat 230 2.0 Gene Chip (Affymetrix, Santa Clara,
CA) and analyzed in the Mayo Clinic Medical Genome Facility (MCF) Gene Expression and Bioinformatics Cores. See S1 and S2 Files for the original gene expression data and S3 File for details on gene expression data analysis and Ingenuity pathway analysis.

**Cross-comparison of gene expression data.** Gene expression signatures from the three cell lines were compared to gene expression signatures from human liver and HCC (NCI cohort) using previously described methods [29, 33]. N1S1 and AS30D HCC molecular prognostic subtypes were classified based on the previously described poor prognostic hepatic stem cell (Cluster A and Subtype HS) or better prognostic hepatocyte (Cluster B and Subtype HCC) human HCC molecular prognostic subtypes [29].

**Cell Proliferation and Metabolism.** Cell proliferation was assessed using the MTT assay per manufacturer guidelines (ATCC, Manassas, VA). Doubling time and metabolic rate (mean ± SD) were calculated from the absorbance data as previously described [36].

**Cellular Heat Stress Protocol.** The indicated cell lines were suspended in complete media in 1.5ml microcentrifuge tubes and heat stressed at the indicated temperatures in an isothermic water bath [24, 37]. Adherent cell lines were prepared following dissociation using non-enzymatic cation-free HBSS/0.5% EDTA. Cells were pre-treated with the designated small molecule inhibitors or vehicle control ± heat stress as indicated. Cells were harvested at the indicated timepoints, rinsed in 1xPBS and snap frozen in liquid N₂ for immunoblot analysis or analyzed with the WST-1 cell viability (Roche, Indianapolis, IN), CaspaseGlo 3/7 apoptosis (Promega, Fitchburg, WI) or colony formation assay.

**Cell Viability and Caspase 3/7 Activity.** At the indicated times post heat stress, WST-1 assay (Roche, Indianapolis, IN) or CaspaseGlo 3/7 assay (Promega, Fitchburg, WI) was performed per manufacturer instruction [37]. Absorbance (WST-1) or luminescence (CaspaseGlo 3/7) was measured on a DTX 880 microplate reader (Beckman Coulter, Chaska, MN) and data were normalized to the non-heat stressed (37°C) vehicle control to determine relative cell viability and plotted versus temperature or Caspase 3/7 activity.

**Soft Agar Colony Formation Assay (Clonogenic Survival).** The cell suspension was mixed with media (adherent cells) or sterile McCoy’s plus medium/agar solution (suspension cells), transferred to sterile tissue culture plates, allowed to set at room temperature for 20–30 minutes and placed in a humidified 37°C, 7.5% CO₂ incubator for 7–14 days. Two to four technical replicates and three biological replicates were used per experimental condition. After 7–14 days, each dish was qualitatively assessed for evidence of colony formation and colonies of 50 or more cells were counted using a light microscope. Percent colony formation per cell number plated was calculated and the data normalized to the non-heat stressed, 37°C vehicle control to calculate percent colony formation.

**Western Immunoblotting.** Whole-cell lysates were separated by SDS-PAGE, electrophoretically transferred to PVDF and blotted for the indicated antigens using the indicated primary antibodies per manufacturer’s instruction followed by incubation with corresponding peroxidase labeled secondary antibodies (1:8000), incubated with enhanced chemiluminesence (ECL, Pierce, Thermo Fisher, Minneapolis, MN), exposed to film (Kodak/Carestream, Rochester, NY) and developed using a Kodak X-Omat M20 processor. Digital images were captured using a Kodak 440CF gel documentation system.

**Kinomeview Profiling.** Per Cell Signaling Technology (CST; Danvers, MA) protocol, 30 µg of total protein was run in each lane for western blotting using a panel of motif antibodies with broad reactivity to serine, threonine and tyrosine phosphorylation and developed as previously described (see S3 File for a description of Kinomeview antibodies and target consensus
Tumor Ablation in Orthotopic N1S1 and AS30D HCC Models. All animal studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the Mayo Clinic (Protocol Number: A31010). All surgery was performed under ketamine/xylazine or inhalation anesthesia; buprenorphine analgesia was administered pre-operatively and all efforts were made to minimize suffering. The N1S1 orthotopic HCC model was developed and tumor-bearing rats were imaged using non-contrast enhanced 3T magnetic resonance imaging (MRI; GE Healthcare, Milwaukee, WI) to measure tumor size and confirm tumor location as previously described [24, 39, 40]. Briefly, adult male Sprague-Dawley rats (400-500g) were randomized to percutaneous thermal ablation (N = 6) or sham ablation (N = 3). All ablation experiments were performed using an FDA-approved 980-nm laser generator (Visualase, Houston, TX) as previously described [24, 37, 39, 40]. Under ultrasound-guidance using an L8-18i transducer (logiq E9 Ultrasound, GE Healthcare, Milwaukee, WI), a bare 400μm core optical laser fiber with a 1.0cm diffusing tip was percutaneously inserted through a 22-gauge introducer sheath at the tumor margin and a 22-gauge needle with a 25-gauge wire thermocouple (Valleylab, Boulder, CO) was inserted 4-5mm from the laser fiber tip within the tumor for intraprocedural temperature monitoring. For the ablation group, tumors were ablated at a power setting of 3 watts (W) under continuous US-monitoring and the ablation stopped when the thermocouple reached 45°C in order to generate an intentional partial ablation. The laser was not turned on for sham-ablated animals. Immediately post-ablation rats underwent both non-contrast and gadolinium-enhanced 3T MRI to image post-ablation tissue changes as previously described [39]. Rats were euthanized at 6 or 24 hours post-ablation to assess early liver/tumor response to thermal injury. Experiments were repeated in the AS30D HCC model using methods previously described [41].

Gross and Microscopic Pathology. Liver/tumor tissue was removed and 2-mm cross-sections cut encompassing the ablation-zone. Vital staining with 0.5% triphenyltetrazolium chloride (TTC; Sigma, St. Louis, MO) was performed as previously described [42]. All specimens were formalin-fixed paraffin embedded (FFPE) and sectioned for histopathologic and immunohistochemical analysis. FFPE sections were stained with hematoxylin-eosin (H&E) or anti-phospho-antibodies against the indicated antigens per manufacturer instruction as previously described [24, 37, 39, 41]. All sections were reviewed in a blinded and random fashion by an experienced pathologist (>20 years).

Human HCC AKT Gene Expression v. Recurrence and Tumor Pathologic Features. Oligonucleotide microarray analysis was performed on RNA from 139 pairs of HCC tumor and adjacent benign tissue from individuals who underwent surgical resection for primary HCC at centers in Asia, Europe and the United States as previously described [29, 32–35]. De-identified anonymized samples were either from patients who had provided verbal or written informed consent or were surgical waste tissues from deceased patients, which were used with IRB approval. The demographic, clinical, follow-up and pathological features for the 139 HCCs were previously summarized [29, 34]. The data have been deposited at Gene Expression Omnibus (GEO/GPL1528, GEO/GPL1529, GEO/GSE1897, GEO/GSE1898and GEO/GSE4024). Briefly, total RNAs were isolated from frozen liver tissue using CsCl density-gradient centrifugation. 20 mg of total RNA from tissues was used to derive fluorescently (Cy-5 or Cy-3) labeled cDNA. At least two hybridizations were performed for each tissue using a dye-swap strategy to eliminate dye-labeling bias. Specimens were analyzed at the US National Cancer Institute using the Human Array-Ready Oligo Set (Version 2.0) containing 70-mer probes of 21,329 genes from Qiagen (Valencia, CA). Expression ratios of each gene were averaged from duplicate experiments and
data were plotted as a log2–fold change of AKT1, AKT2 and AKT3 mRNA expression, tumor over benign. Differences between the Kaplan-Meier curves of HCC patients with up-regulated or down-regulated AKT1, AKT2 and AKT3 expression in the HCC tissue in comparison with the adjacent benign tissue were analyzed with the log rank test. AKT1, AKT2 and AKT3 mRNA expression, tumor over benign, was compared by HCC prognostic cluster (A versus B), subtype (hepatocyte HC v. hepatoblast HS), tumor grade, vascular invasion and metastasis [29, 33].

**Statistical Analyses.** Statistical analyses were performed using Prism 5.0 (GraphPad Software, Inc., La Jolla, CA). Differences between treatment groups were compared with an unpaired $t$ test (or Exact Mann-Whitney test) or one-way analysis of variance (ANOVA) followed by post-hoc pairwise comparison using an unpaired $t$ test (or Exact Mann-Whitney test). Non-linear regression curve fitting was used to calculate a heat stress $IT_{50}$. $IT_{50}$ was defined as the temperature that induced a 50% reduction in cell viability relative to 37°C control for the indicated exposure time. See S3 File for details on cumulative equivalent minutes at 43°C (CEM43) calculations [43].

**Results**

Comparative genomic and biological characterization of Clone9 rat hepatocyte and N1S1 and AS30D rat HCC cell lines

**Comparative Genomics.** Cross-comparison of the Clone9 rat hepatocyte and N1S1 and AS30D rat HCC cell line gene expression signature with orthologous human normal liver and HCC gene expression data demonstrated that the N1S1 cell line has a gene-expression signature consistent with a poor prognostic hepatic stem cell (Cluster A and Subtype HS) HCC molecular subtype while the AS30D cell line has a gene expression signature consistent with a better prognostic hepatocyte (Cluster B and Subtype HC) HCC molecular subtype (Fig 1). Moreover, the Clone9 rat hepatocyte cell line demonstrated a gene expression signature consistent with benign human liver (S1 Fig). The corresponding gene expression data for the N1S1 HCC, AS30D HCC and Clone 9 hepatocyte cell lines are available in S1 and S2 Files.

**Cell Proliferation, Metabolic Rate and Colony Formation.** Doubling time (hours) and metabolic rate (uU/hour/cell) are summarized in S1 Table. Doubling time of HCC cells relative to Clone9 hepatocytes was approximately 1.3 times faster for N1S1 ($p<0.001$) and 1.3 times slower for AS30D ($p<0.01$) while doubling time of N1S1 was 1.8 times faster than AS30D ($p<0.0001$). The metabolic rate of HCC cells relative to Clone9 hepatocytes was 2.4 times higher for N1S1 ($p<0.0001$) and 1.7 times higher for AS30D ($p<0.001$) while the metabolic rate of N1S1 was 1.4 times higher than AS30D ($p<0.01$). The N1S1 and AS30D rat HCC cell lines demonstrated evidence of colony formation in soft agar whereas the Clone9 rat hepatocyte cell line formed very few discrete, countable colonies (images not shown). Morphologically, the N1S1 colonies showed irregular borders and evidence of cell migration while the AS30D colonies showed regular borders and no evidence of cell migration (S2 Fig).

**Ingenuity Pathway Analysis.** The top biological functions, molecular and cellular functions, canonical pathways, transcription factors and up-regulated and down-regulated molecules based on comparison of differentially expressed genes for N1S1 HCC v. Clone9 hepatocyte and AS30D HCC v. Clone9 hepatocyte are summarized in S2–S5 Tables.

Poor prognostic hepatic stem cell HCC subtype demonstrates enhanced survival to heat stress

To investigate the effects of temperature and exposure time (i.e. thermal dose) on the kinetics of heat stress induced cytotoxicity, N1S1 and AS30D HCC cell lines were heat stressed across
the temperature range from physiologic (37°C) to complete cytotoxicity (60°C) for 2 or 10 minutes and assessed for cell viability at 6 to 72 hours post-heat stress [24]. The dose-response curves demonstrated a left shift for the 10-minute versus 2-minute exposure times for both cell lines (Fig 2A and 2B). The IT\textsubscript{50} (in °C) for heat stress exposure times of 2 and 10 minutes are summarized in Table 1. For the 10 minute exposure time, the IT\textsubscript{50} was significantly higher for the N1S1 compared to AS30D cells at 48 and 72 hours post heat stress (p < 0.0001). After normalizing these heat stress exposure time and temperature data using the equation for continuous equivalent minutes at 43°C (CEM43), the heating time in minutes at 43°C to achieve a 50% kill (IT\textsubscript{50} CEM43 [95% Confidence Interval]) was significantly longer for the N1S1 relative to the AS30D cell line (1.84 times longer; 105.8 minutes [84.6 to 132.5] v. 57.5 minutes [45.3 to 72.9], respectively) (Fig 2C and 2D). Taken together, the results of these experiments suggest that the poor prognostic HCC molecular subtype (N1S1) requires a higher thermal dose for cell killing than the better prognostic HCC molecular subtype (AS30D).

Next, because both the N1S1 and AS30D HCC cell lines demonstrated different sensitivities to heat stress, we assessed the dose-dependent effects of heat stress on HCC clonogenic survival as an in vitro model for recurrence following heat stress. Heat stress at 40°C had no effect on colony formation relative to the untreated control (37°C) while heat stress at ≥50°C resulted in complete loss of colony formation in both cell lines (Fig 2E and 2F). Heat stress at 45°C resulted in a significant reduction in colony formation relative to the untreated control in both N1S1 and AS30D cell lines (p < 0.02 and p < 0.001, Fig 2E and 2F, respectively). However, the relative percent colony formation at 45°C was significantly greater in the N1S1 versus the AS30D cell line (3.5 fold; 16.1%±2.5% versus 4.7%±1.2%, respectively, p < 0.02). These data identified experimental heat stress conditions which result in in vitro clonogenic survival in both cell lines (45°C for 10 minutes) and suggest that different molecular subtypes of HCC may have a different capacity to recover and progress following sublethal heat stress.

Sublethal heat stress induces AKT and ERK survival signaling in vitro and thermal ablation induces AKT and ERK phosphorylation at the tumor ablation margin in vivo

Sublethal heat stress induces rapid changes in kinome-wide protein phosphorylation in HCC cells and hepatocytes. Preliminary experiments identified in vitro heat stress conditions (45°C for 10 minutes) that induce a significant reduction in cell survival but still result in colony formation (Fig 2E and 2F). This model recapitulates the thermal injury experienced at the margin of the ablation zone where both neoplastic and parenchymal cells experience heat stress that may or may not induce complete cell killing. Based on the kinetics of heat stress induced cytotoxicity, we hypothesized that sublethal heat stress induces rapid changes in cell signaling. Using this experimental model of post heat stress in vitro recurrence, we sought to examine global changes in protein phosphorylation and other post-translational modifications that are responsive to heat stress in order to identify candidate kinase families and pathways that may regulate HCC cell survival to heat stress. Immunoblot analysis identified significant changes in
Heat Stress Induced AKT Signaling Mediates HCC Survival to Thermal Ablation

A. N1S1 HCC

B. AS30D HCC

C. $\text{IT}_{50} \text{ CEM43} = 105.8 \text{ min}$

D. $\text{IT}_{50} \text{ CEM43} = 57.5 \text{ min}$

E. $p<0.02$

F. $p<0.001$
one or more bands for the AKT substrate motif, RXX(s/t) and tXR motif, tXR across all cell
lines (S3 Fig). Modest changes in phosphorylation were observed for CK, PKA, PKC, PLC and
Phospho-Thr-Pro motif antibodies (data not shown). These data demonstrate that heat stress
induces rapid changes in the global phosphoproteome in both hepatocytes and HCC cells of
rat and human origin.

Sublethal heat stress induces rapid AKT and ERK phosphorylation in vitro and thermal
ablation induces AKT and ERK phosphorylation at the tumor ablation margin in vivo.

Kinomeview® profiling showed that heat stress induces rapid changes in phosphorylation of
AKT substrates containing the RXX(s/t) motif as well as phosphorylation of proteins contain-
ing the phosphor-Thr-X-Arg/Lys motif such as Raf (MAP3K), a serine/threonine kinase mem-
ber of the mitogen-activated kinase family known to be phosphorylated at threonine followed
by Lys at the +2 position (S3 Fig) [44]. Phosphorylated Raf then phosphorylates and activates
MEK1/2 (MAP2K), a tyrosine/threonine kinase which in turn phosphorylates and activates
ERK1/2 (MAPK3/MAPK1), a serine/threonine kinase [45]. Moreover, AKT is dually phos-
phorylated at Thr308 by PI3K signaling and Ser473 by mammalian target of rapamycin com-
plex 2 (mTORC2) signaling while ERK1/2 is dually phosphorylated at Threonine202 and
Tyrosine 204 by MEK for maximal activation [45–47]. The AKT and ERK pathways play criti-
cal roles in cell survival and proliferation and both are frequently dysregulated in numerous
cancers, including HCC [45, 48–54].

Given the results of the Kinomeview® analysis, we hypothesized that heat stress induces
phosphorylation of AKT and ERK signaling. To test this hypothesis, N1S1 and AS30D cells
were heat stressed and analyzed using phospho-specific antibodies against AKT and ERK by

| Table 1. IT<sub>50</sub> (°C)<sup>†</sup> for heat stress induced cytotoxicity in N1S1 and AS30D HCC cells. |
|-----------------|-----------|-----------|-----------|-----------|
|                  | 6 Hour *  | 24 Hour * | 48 Hour * | 72 Hour * |
| N1S1 HCC         | >57.5     | 52.5 (51.3, 53.8) | 49.3 (48.5, 50.0) | 49.3 (48.3, 50.4) |
| AS30D HCC        | >55.0     | 51.7 (50.7, 52.6) | 48.9 (48.6, 49.2) | 48.8 (48.5, 49.0) |
| 10min IT<sub>50</sub> (°C) | 6 Hour *  | 24 Hour *  | 48 Hour *  | 72 Hour *  |
| N1S1 HCC         | 53.1 (50.5, 55.8) | 47.4 (46.1, 48.7) | 45.7 (45.5, 45.8) | 45.9 (45.6, 46.2) |
| AS30D HCC        | 51.8 (50.5, 53.0) | 47.4 (46.6, 48.2) | 44.4 (44.2, 44.6) | 44.5 (44.3, 44.7) |

Data are presented as IT<sub>50</sub> (95% confidence interval). Comparison of 10 min IT<sub>50</sub> at 48 and 72 hours
between N1S1 and AS30D (p<0.0001)

* indicates the time point post heat stress the cells were assayed for viability.
† IT<sub>50</sub> is defined as the temperature that results in a 50% reduction in cell viability relative to 37°C control for
the indicated exposure time.
western immunoblotting (Fig 3A and 3B). Compared to baseline, heat stress induced a rapid increase in phosphorylation of both AKT and ERK immediately after the heat stress in both HCC cell lines. This increased phosphorylation of both AKT and ERK was sustained for at least 2 hours in the N1S1 cell line but began to decrease by 2 hours post heat stress in the AS30D cell line. Additionally, heat stress induced a time-dependent increase in the phosphorylation of AKT substrates 1) Bad, 2) FoxO3a/FoxO1, and 3) glycogen synthase kinase-3 (GSK3β), (Fig 3C and 3D). Phosphorylation of Bad, FoxO3a/FoxO1 and GSK3β by AKT negatively regulates their activity, thereby promoting cell survival [55–57]. Finally, similar experiments confirmed that heat stress induced a rapid, differential increase in the phosphorylation of AKT, GSK3β and ERK in a panel of eight human HCC cell lines (S4 Fig).

Having identified that heat stress activates both AKT and ERK signaling in a range of HCC cell lines, we sought to confirm whether these pathways are induced by thermal ablation in vivo (S5 and S6 Figs). Gross analysis of the ablation zone in situ (Fig 4A) and in cross-section with TTC vital staining demarcated the ablation margin and boundaries between viable (red) and non-viable (white) tumor and liver tissue within the ablation zone (Fig 4B). H&E and immunohistochemical analysis of the ablation zone after laser ablation demonstrated discrete morphologic regions within the ablation zone that correlated with TTC vital staining (Fig 4D) and markedly increased immunostaining for phospho-AKT (Fig 4F) and phospho-ERK (Fig 4H) at the tumor ablation margin but not at distances further from the tumor ablation margin or at the liver ablation margin (S7 Fig for phospho-AKT). On the other hand, there was no evidence of increased immunostaining for phospho-AKT (Fig 4E) and phospho-ERK (Fig 4G) in the tumor or at the margin between liver and tumor in the sham ablation group. In short, these data suggest that thermal ablation induces AKT and ERK phosphorylation at the tumor ablation margin in vivo. Similar results were obtained with the AS30D orthotopic HCC model (S8 Fig).

Sublethal heat stress induces PI3K/mTOR and MEK-dependent AKT and ERK signaling, respectively, and inhibition of the PI3K-AKT-mTOR pathway but not MEK enhances heat stress induced HCC cell killing

Next we sought to investigate the upstream mechanisms mediating heat stress induced AKT and ERK signaling. Western immunoblotting demonstrated that inhibition of PI3K/mTOR with NVP-BEZ235 and MEK with AZD6244 blocked constitutive and heat stress induced AKT and ERK phosphorylation, respectively (Fig 5A) [58, 59]. Additionally, heat stress induced autophosphorylation of mTOR at Ser2481, a marker for activation of mTORC2 but did not induce phosphorylation of mTOR at Ser2448, a marker for mTORC1 signaling [60]. Inhibition of PI3K/mTOR blocked both mTORC1 and mTORC2 kinase signaling. Lastly, MEK inhibition alone increased basal AKT phosphorylation in the N1S1 cell line but not the AS30D cell line, suggesting differential cross-talk between PI3K-AKT-mTOR and RAS-RAF-MEK-ERK signaling between these two cell lines. Viability assessment confirmed that dual PI3K/mTOR inhibition has strong cytotoxic effects as a single agent and enhances heat stress induced HCC cell killing in both cell lines (Fig 5B and 5C). MEK inhibition induced modest, dose-dependent cytotoxic effects as a single agent in the AS30D cell line (Fig 5C) but an IT50 was not achieved in the N1S1 cell line, even at the 500nM dose (Fig 5B). Moreover, inhibition of MEK did not enhance heat stress induced HCC cell killing in the N1S1 cell line and only moderately increased heat stress induced cell killing in the AS30D cell line. Finally, combination PI3K/mTOR and MEK inhibition did not further enhance heat stress induced cell killing over PI3K/mTOR inhibition alone in either cell line [61]. Given these findings, the PI3K-AKT-mTOR pathway was chosen for further investigation.
Western immunoblotting demonstrated that both NVP-BEZ235 and LY294002 inhibitors prevented both constitutive and heat stress induced AKT phosphorylation at Thr308 and Ser473 in both cell lines (S9A Fig) [62]. Viability assessment demonstrated that both PI3K and dual PI3K/mTOR inhibition increased heat stress-induced HCC cell killing over heat stress or
inhibitor alone (p<0.001; S9A and S9B Fig). Moreover, the dual PI3K/mTOR inhibitor NVP-BEZ235 was as efficacious (N1S1; S9B Fig) if not more (AS30D; S9C Fig) than the PI3K inhibitor LY294002. Based on the potency and clinical relevance of the dual PI3K/mTOR inhibitor NVP-BEZ235, this drug was chosen for subsequent experiments. Further experiments confirmed that inhibition of PI3K/mTOR enhances heat stress induced HCC cell killing over heat stress or drug alone (p<0.0001) (Fig 6A and 6B). Additionally, PI3K/mTOR inhibition in combination with heat stress increased caspase 3/7 activity (p<0.02; Fig 6C and 6D) and generation of cleaved caspase 3 in a dose-dependent manner (Fig 6E).

PI3K/mTORC2-dependent AKT signaling is a central mediator of HCC cell survival to heat stress

The observation that sublethal heat stress induces rapid PI3K/mTOR dependent AKT signaling and that inhibition of PI3K/mTOR-dependent AKT signaling enhances heat stress induced HCC cell killing raises the question whether blockade of the entire PI3K-AKT-mTOR pathway vs. AKT alone mediates the increased HCC cell killing to heat stress. As such, we sought to determine which components of the PI3K-AKT-mTOR pathway mediate HCC cell survival to heat stress using a clonogenic survival assay as an in vitro model of recurrence (Fig 2E and 2F; S2 Fig). Inhibition of both PI3K/mTORC1/2 (NVP-BEZ235) (Fig 7A and 7D) and AKT (MK-2206) (Fig 7B and 7E) blocked heat stress induced phosphorylation of AKT at Ser473 and Thr308 and significantly decreased HCC clonogenic survival to sublethal heat stress [58, 63]. In fact, inhibition of PI3K/mTORC1/2 in combination with sublethal heat stress resulted in no colony formation at higher doses of NVP-BEZ235. Similar findings were obtained in the human HCC cell line Hep3B (S10A and S10B Fig). However, preferential inhibition of mTORC1 (Rapamycin) did not block heat stress induced AKT activation at Ser473 or Thr308 and had minimal effect on reducing HCC cell survival to sublethal heat stress, even at higher doses (Fig 7C and 7F) [64]. Of note, mTORC1/2 and mTORC1 inhibition alone significantly reduced Hep3B clonogenic survival suggesting that this HCC cell line may in part be mTOR-dependent at baseline (S10C Fig).

AKT isoforms are differentially overexpressed in human HCC and correlate with worse HCC tumor characteristics and prognosis

Given that AKT signaling may be an important mediator of HCC cell survival to thermal ablation induced heat stress, we sought to investigate the potential clinical significance of the three AKT isoforms in human HCC. There was increased expression in the HCC tumor compared to the benign adjacent tissue in the following proportions of HCCs: AKT1 (48.2%; Fig 8A), AKT2 (29.1%; Fig 8B) and AKT3 (70.0%; Fig 8C). Recurrence analysis showed that patients with tumors expressing the highest versus lowest levels of AKT1 had a more rapid rate of tumor recurrence after surgical resection (P<0.05; Fig 8D). AKT2 and AKT3 expression were
### A

|          | N1S1                  | AS30D                  |
|----------|-----------------------|------------------------|
| BEZ235   | - - + + - - + +      | - - + + - - + +       |
| AZD6244  | - - + + + + + +      | - - + + + + + +       |
| HEAT STRESS | - + - - + + + -    | - + - - + + + +     |

- **p-AKT Thr308**
- **p-AKT Ser473**
- **Total AKT**
- **p-ERK Thr202/Tyr204**
- **Total ERK**
- **p-mTOR Ser2481**
- **p-mTOR Ser2448**
- **β-Actin**

### B

![Graph showing % Viability (Relative to Control)](image)

**Legend:**
- Vehicle
- BEZ235 0.1μM
- AZD6244 0.25μM
- BEZ235 + AZD6244 0.25μM
- BEZ235 + AZD6244 0.50μM

### C

![Graph showing % Viability (Relative to Control)](image)

**Legend:**
- Vehicle
- BEZ235 0.1μM
- AZD6244 0.25μM
- BEZ235 + AZD6244 0.25μM
- BEZ235 + AZD6244 0.50μM
not associated with more rapid recurrence (data not shown). Moreover, HCC tumors with a poor prognostic cluster A ($p < 0.0001$; Fig 8E), hepatic stem cell (HS) subtype ($p < 0.01$; Fig 8F), higher tumor grade ($p < 0.03$; Fig 8G), vascular invasion ($p < 0.05$; Fig 8H) and metastasis ($p < 0.01$; Fig 8I) had significantly greater expression of AKT3. Given these findings we examined AKT isoform protein expression in our in vitro HCC model system (Fig 1). Western immunoblotting showed that all four cell lines express AKT1 and minimal AKT2 (S11 Fig). Interestingly, the N1S1 cell line, which has a poor prognostic hepatic stem cell molecular subtype of HCC (Cluster A and Subtype HS; Fig 1), also expresses high levels of AKT3, findings consistent with the human HCC gene expression data (Fig 8E and 8F). On the other hand, the AS30D cell line, which subclassifies with the better prognostic hepatocyte molecular subtype of HCC (Cluster B and Subtype HC) and the human Hep3B and HuH7 HCC cell lines do not express AKT3. In summary, these data show that AKT isoforms are differentially overexpressed in human HCC tumors and may have biological (AKT3) and prognostic significance (AKT1) in an isoform-dependent manner.

**Discussion**

The clinical use of thermal ablation for HCC has outpaced the understanding of the basic molecular mechanisms mediating HCC-specific response to heat stress, particularly at the ablation margin where tumor recurrence remains a challenging problem. The experiments herein sought to address the following basic and translational questions regarding mechanisms of HCC cell survival to thermal ablation induced heat stress using a combination of in vitro, in vivo and patient based approaches: 1) What is the biological and clinical relevance of the N1S1 and AS30D HCC cell lines as models for testing thermal ablation hypotheses? 2) What signaling pathway(s) mediate HCC cell survival to sublethal heat stress? 3) Does inhibition of these pathway(s) in combination with heat stress decrease HCC cell survival? 4) Do these signaling pathways have biologic or prognostic significance to human HCC?

Previous studies have demonstrated that the N1S1 and AS30D HCC cell lines are tumorigenic when implanted in the liver of immunocompetent rats, are phenotypically distinct and are feasible models for testing thermal ablation hypotheses in vivo [24, 37, 39–41]. However, the biologic and clinical relevance of these cell lines has not been characterized, and the generalizability of this model system to human liver and HCC has remained unknown. As such, we sought to characterize the biological properties and clinical relevance of this in vitro model system. The comparative genomic data showed that the gene expression signature of the Clone 9 normal rat hepatocyte cell line is consistent with benign human liver while the gene expression signature of the N1S1 HCC cell line corresponds to a poor prognostic hepatic stem cell molecular subtype (Cluster A and Subtype HS) and the AS30D HCC cell line corresponds to a better prognostic hepatocyte (Cluster B and Subtype HC) of human HCC [29]. These three cell lines have several advantages as a candidate in vitro model system for examining molecular mechanisms mediating the variation in cellular response to heat stress between hepatocytes and different sub-types of HCC: 1) they are derived from the same cell type—hepatocyte—from the
Heat Stress Induced AKT Signaling Mediates HCC Survival to Thermal Ablation

A

% Viability (Relative to Control)

Vehicle Control BEZ235

Heat Stress - + - +

B

% Viability (Relative to Control)

Vehicle Control BEZ235

Heat Stress - + - +

C

Caspase 3/7 Activity (Relative to Control)

Vehicle Control BEZ235

Heat Stress - + - +

D

Caspase 3/7 Activity (Relative to Control)

Vehicle Control BEZ235

Heat Stress - + - +

E

N1S1

BEZ235

Heat Stress

Vehicle 0.1μM 0.5μM 1.0 μM

- + - + - +

Cleaved Caspase 3

β-Actin

AS30D

Vehicle 0.1μM 0.5μM 1.0 μM

- + - + - +

Cleaved Caspase 3

β-Actin
same species of rat; 2) they are phenotypically and biologically distinct representing two ends of the HCC disease spectrum and 3) the HCC cell lines are tumorigenic which facilitates translation from in vitro to in vivo thermal ablation studies ([S6 Table] for cell line comparison) [29].

Having established the biological and prognostic significance of the N1S1 and AS30D HCC cell lines, we sought to investigate the thermal-dose dependent effects of heat stress on HCC cytotoxicity using clinically relevant experimental heat stress conditions as well as the impact of HCC biological heterogeneity on sensitivity to heat stress induced cell killing in vitro. The in vitro findings demonstrate that the poor prognostic hepatic stem cell subtype of HCC (N1S1) requires a higher thermal dose for cell killing and has a greater capacity to recover and progress following sublethal heat stress than the better prognostic hepatocyte subtype of HCC (AS30D). Importantly, these studies identified experimental heat stress conditions (45°C for 10 minutes) that result in significantly different survival between HCC subtypes using experimental heat stress conditions relevant to the clinical thermal ablation zone [43, 65, 66]. These experimental conditions, defined as sublethal heat stress, were chosen to investigate the molecular mechanisms mediating the variation in response to sublethal heat stress between these two cell lines. Taken together, these data suggest that the molecular subtype of HCC may play a fundamental role in variation in HCC response to heat stress, particularly at lower thermal doses.

Next we sought to identify candidate signaling pathways that may mediate HCC cell survival to sublethal heat stress. The findings from the initial kinase screen suggested that both AKT and ERK signaling pathways may be induced by sublethal heat stress. Both the AKT and ERK pathways are known to play critical roles in cell growth, survival and proliferation and are frequently dysregulated in numerous cancers including HCC and predict a poorer prognosis [45, 48–54]. Subsequent experiments confirmed that sublethal heat stress induces rapid AKT and ERK phosphorylation in both rat and human HCC cells in vitro, findings consistent with a previous study [67]. However, these data build on previous studies by identifying important differences in the kinetics of heat stress induced AKT and ERK phosphorylation depending on the molecular subtype of HCC under clinically relevant heat stress conditions. Additionally, sublethal heat stress induced a time-dependent increase in the phosphorylation of AKT substrates Bad, FoxO3a/FoxO1 and glycogen synthase kinase-3 (GSK3β) whose phosphorylation negatively regulates their pro-cell death functions, thereby promoting a survival phenotype [55–57]. The in vivo ablation experiments confirmed that thermal ablation induces AKT and ERK phosphorylation at the HCC tumor ablation margin in vivo, the region of the ablation zone at highest risk for tumor recurrence. Given the known pro-survival effects of AKT and ERK signaling, these pathways were chosen as candidate mediators of HCC cell survival to sublethal heat stress for further investigation.

Next, we sought to determine if inhibition of AKT and ERK pathways in combination with heat stress enhances heat stress induced HCC cell killing. Experiments confirmed that inhibition of heat stress induced AKT signaling with the dual PI3K/mTOR inhibitor NVP-BEZ235...
increased heat stress induced HCC cell killing. Conversely, inhibition of ERK signaling with the MEK inhibitor did not enhance heat stress induced HCC cell killing in the N1S1 cell line and only modestly increased heat stress induced cell killing in the AS30D cell line. The difference in the efficacy of MEK inhibition between these two cell lines may in part be explained by

Fig 7. Effect of PI3K/mTORC1/2, AKT and mTORC1 inhibition on heat stress AKT signaling and clonogenic survival in HCC cells. (A-C) N1S1 and (D-F) AS30D HCC cells pre-treated with a dose-iteration of (A,D) the dual PI3K/mTORC1/2 inhibitor NVP-BEZ235, (B,E) the AKT inhibitor MK-2206 (C, F) the mTORC1 inhibitor rapamycin or vehicle control (0.1% DMSO) followed by heat stress (45°C) or control (37°C) for 10 minutes were harvested immediately post-heat stress for western immunoblotting or plated for the colony formation assay. For immunoblotting, whole-cell lysates were subjected to western immunoblotting for phospho- and total AKT. β-actin was used as a loading control. Representative images from 1 of 3 independent experiments are shown. For the colony formation assay, colonies of 50 or more cells were counted 7 (N1S1) or 10 (AS30D) days after plating using a light microscope. Percent colony formation per cell number plated was calculated and the data normalized to the non-heat stressed, 37°C control to calculate percent colony formation relative to 37°C control. Data are presented as mean ± SEM of 3 independent experiments (One-way ANOVA followed by post-hoc pairwise comparison using an unpaired t-test). ns P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001

doi:10.1371/journal.pone.0162634.g007
the paradoxical activation of AKT signaling upon treatment with the MEK inhibitor in the N1S1 cell line but not in the AS30D cell. As such, these findings would support the hypothesis that activation of AKT signaling may be a potential mechanism of resistance to treatment with inhibitors of RAS-RAF-MEK-ERK signaling in certain sub-types of HCC. Lastly, dual inhibition of heat stress induced AKT and ERK signaling did not further enhance heat stress induced HCC cell killing over AKT (PI3K/mTOR) inhibition alone [61]. Additional experiments further confirmed that inhibition of heat stress induced AKT signaling via PI3K or PI3K/mTOR
inhibition significantly enhanced heat stress induced HCC cell killing, caspase 3/7 activity and cleaved caspase 3 generation, suggesting that inhibition of PI3K/mTOR may enhance heat stress induced cell killing by in part increasing apoptosis.

Next we sought to determine which components of the PI3K-AKT-mTOR pathway including PI3K/mTORC1/2, mTORC1 and/or AKT mediate HCC cell survival to heat stress using a clonogenic survival assay as an in vitro model of recurrence. These experiments provided further evidence that blocking functional activation of AKT via PI3K/mTORC2-dependent AKT phosphorylation or directly blocking AKT function significantly decreased HCC survival to heat stress while mTORC1 inhibition had no impact. Dual PI3K/mTORC2 inhibition with NVP-BEZ235 was the most efficacious and potent enhancer of heat stress induced HCC cell killing. These findings are consistent with previous studies demonstrating that dual PI3K/mTOR inhibitors enhance antitumor activity when used in combination with radiation, cytotoxic chemotherapy and molecularly targeted agents [58, 68–70]. In addition, it is known that inhibition of mTORC1 signaling alone using rapamycin may potentiate PI3K activation through inhibition of the mTORC1/S6K1 negative feedback loop. This may in part explain the lack of efficacy of rapamycin. Inhibition of both PI3K and mTOR kinase activity is now recognized as more effective at inhibiting AKT phosphorylation and activation [71]. Taken together, these data provide evidence that PI3K/mTORC2-dependent AKT signaling is a central mediator of HCC cell survival to heat stress and that the increased HCC cell killing is independent of mTORC1 signaling.

Finally, given that these data support that AKT signaling is an important mediator of HCC cell survival to thermal ablation induced heat stress, we sought to investigate the potential clinical significance of the three AKT isoforms in human HCC. Prior studies have shown that AKT isoform 1, 2 and 3 have diverse roles in mediating tumorigenesis and cancer cell survival [72–75]. Increased expression of AKT1, but not AKT3 or AKT2, predicted more rapid recurrence following surgical resection of HCC. Additionally, patients with tumors that had a poor prognostic hepatic stem cell subtype, vascular invasion and metastasis showed increased expression of AKT3 expression. Of note, the N1S1 HCC cell line expressed high levels of AKT3 whereas the other cell lines did not, thereby providing further evidence for the clinical relevance of the N1S1 HCC cell line as a worse prognostic subtype of human HCC. One hypothesis is that gain of AKT3 expression is associated with worsening tumor biology and phenotypic de-differentiation. Overall, these data provide further molecular insight into how AKT isoforms are differentially overexpressed in human HCC tumors and may have biological (AKT3) and prognostic significance (AKT1) in an isoform-dependent manner.

There are limitations to these studies. First, the genomic data and biological pathway analysis do not provide specific mechanistic insight into the regulation of HCC oncogenesis in the N1S1 and AS30D rat HCC cell lines. Rather, these data are hypothesis generating and provide a framework for understanding the biological and translational relevance of this model system to human HCC. Second, pharmacologic inhibition methods with small molecule kinase inhibitors were used to investigate heat stress induced PI3K-AKT-mTOR signaling. Although these are well-characterized, specific kinase inhibitors, they are prone to off target effects, particularly at higher doses. As such, multiple structurally dissimilar inhibitors with a dose-titration were used to examine the dose-dependent effects. Nonetheless, future gain and loss of function experiments will help to further delineate which component(s) of the PI3K-AKT-mTOR pathway and/or which AKT isoforms mediate HCC cell survival to heat stress. Moreover, the in vitro findings warrant further validation in clinically and biologically relevant HCC animal models using both pharmacologic and genetic methods of AKT inhibition. Third, while these experiments focused on heat stress induced AKT and ERK signaling as candidate mediators of HCC cell survival to heat stress, other survival pathways such as p38 MAPK, SAP/JNK and TGF-β signaling warrant further investigation.
Conclusions
In summary, these findings support the hypothesis that heat stress induced, PI3K/mTORC2--dependent AKT signaling is a central mediator of HCC cell survival to heat stress and provide a mechanistic rationale for adjuvant PI3K-AKT-mTOR inhibition in combination with thermal ablation. Moreover, the N1S1 and AS30D HCC cell lines may serve as a relevant model not only of two biologically diverse molecular prognostic subtypes of HCC but also for investigating the isoform specific role of AKT in HCC tumorigenesis and survival to thermal ablation induced heat stress.

Supporting Information

S1 Fig. Cross comparison of integrated gene expression data from Clone9 rat hepatocyte and N1S1 and AS30D rat HCC cell lines with human benign liver and HCC (NCI cohort). Hierarchical clustering analysis of integrated gene expression data from rat cell lines and human HCC tissues. Gene expression data from rat cell lines and human HCC tissues were independently centralized across samples to remove baseline differences between the two data sets. Genes with an expression level at least 2-fold different relative to the median value across tissues in at least 3 tissues in the rat data set were selected for hierarchical clustering analysis (2,759 unique gene). The data are presented in matrix format in which rows represent individual gene and columns represent each tissue. Each cell in the matrix represents the expression level of a gene feature in an individual tissue. The red and green color in cells reflect relative high and low expression levels respectively as indicated in the scale bar (log2 transformed scale). ST = BL = Benign Liver. HCC = Hepatocellular Carcinoma.

S2 Fig. Soft-agar colony formation of N1S1 and AS30D rat HCC cell lines. Representative photomicrographs of N1S1 (A,C) and AS30D (B,D) colonies after 10 days at 100x (A,B) and 200x (C,D) magnification.

S3 Fig. Immunoblot analysis of kinome-wide changes in protein phosphorylation in response to heat stress in hepatocytes and HCC cells. (A) Phospho-AKT Substrate RXX (S\(^\text{T}\)) immunoblot; (B) Phospho-Thr-X-Arg Motif T\(^\text{X}(K/R)\). (C) β-Actin (top) and Gel Stain (bottom) control immunoblots. Odd numbered lanes are without heat stress and even numbered lanes are with heat stress. Lanes 1,2 = Clone rat hepatocyte; Lanes 3,4 = N1S1 rat HCC; Lanes 5,6 = AS30D rat HCC; Lane 7,8 = HuH7 human HCC; Lanes 9,10 = Hep3B human HCC; and Lanes 11,12 = PLC/PRF/5 human HCC.

S4 Fig. Effect of sublethal heat stress on AKT and ERK signaling in human HCC cells. The indicated cell lines were heat stressed (45°C) or control (37°C) for 10 minutes, harvested immediately post-heat stress and whole-cell lysates were subjected to western immunoblotting using phospho-specific antibodies against AKT, GSKβ and ERK. β-actin was used as a loading control.

S5 Fig. Percutaneous US-guided laser ablation with temperature monitoring in orthotopic N1S1 HCC model. A) Percutaneous insertion of laser fiber (†) and thermocouple (‡) into N1S1 tumor under US guidance. B) Short axis and C) long axis US images demonstrate a hypoechoic tumor (white arrowheads) with the hyperechoic-appearing laser fiber and
thermocouple located in the inferior-lateral and superior-medial aspects of the tumor, respectively.

S6 Fig. Representative pre- and post-ablation non-contrast and gadolinium-enhanced axial fast spin echo (FSE) T2- and T1-weighted MR images of orthotopic N1S1 HCC model. A) Pre-ablation and B-F) post-ablation 3T MR images demonstrate A) a hyperintense T2-weighted N1S1 tumor pre-ablation (denoted by white arrowhead), B) decreased T2-signal and C) decreased T1-signal relative to liver on immediate post-ablation non-contrast enhanced MRI. Gadolinium-enhanced T1-weighted MR images at D) 3-minutes E) 6-minutes and F) 10 minutes post-injection demonstrate time-dependent enhancement of the background liver and a hypoenhancing zone in the region of the tumor ablation.

S7 Fig. Representative phospho-AKT immunostaining of the tumor ablation and liver ablation margins in a laser-ablated orthotopic N1S1 tumor. A) low power (25x) and C) higher power (50x) photomicrographs demonstrate very few cells staining positive (brown) for phospho-AKT in the background liver or at the liver-ablation margin (denoted by black arrowheads). B) low power (25x) and D) higher power (50x) photomicrographs demonstrate focal areas of markedly increased phospho-AKT immunostaining at the tumor ablation margin (denoted by black arrowheads) with decreased immunostaining further from the ablation margin toward the non-ablated tumor.

S8 Fig. Representative gross and microscopic pathology and immunohistochemical staining of the ablation zone 24-hours post-ablation in the orthotopic AS30D HCC model. Photomicrographs (100x) of H&E stained sections (A,B) demonstrate A) the liver-tumor margin of a sham-ablated tumor (denoted by white arrowhead) and the B) tumor-ablation margin of a laser ablated tumor (denoted by white arrowheads). Corresponding photomicrographs (100x) of p-AKT (C,D) and p-ERK (E,F) immunostained sections demonstrate markedly increased AKT (D) and minimally increased ERK (F) phosphorylation at the tumor-ablation margin (denoted by white arrowheads) in the laser-ablated tumor but minimal AKT (C) and ERK (E) phosphorylation in the tumor, background liver or at the tumor-liver margin (denoted by white arrowheads) in the sham-ablated tumor. (*) denotes background liver.

S9 Fig. Effect of PI3K and PI3K/mTOR inhibition on heat stress induced AKT signaling and cytotoxicity in HCC cells. (A) N1S1 and AS30D cells were pre-treated for one hour with LY294002 (50μM), NVP-BEZ235 (0.5μM) or vehicle control (0.1% DMSO) followed by heat stress (45°C) or control (37°C) for 10 minutes. Immediately post-heat stress whole-cell lysates were subjected to western immunoblotting for phospho- and total AKT. β-actin was used as a loading control. Representative images from 2 independent experiments (B, C) N1S1 and AS30D cells pre-treated for one hour with LY294002 (10 μM), NVP-BEZ235 (0.1 μM) or vehicle control (0.1% DMSO) followed by heat stress (45°C) or control (37°C) for 10 minutes were assessed with WST-1 viability assay at 72 hours post-heat stress. Data were normalized to 37°C vehicle control and presented as mean±SD (N = 4 independent cultures) (One-way ANOVA followed by post-hoc pairwise comparison using an unpaired t-test).

S10 Fig. Effect of PI3K/mTORC1/2, AKT and mTORC1 inhibition on clonogenic survival to sublethal heat stress in Hep3B HCC cells. Human Hep3B HCC cells pre-treated with a
dose-titration of the (A) the dual PI3K/mTORC1/2 inhibitor NVP-BEZ235, (B) the AKT inhibitor MK-2206 (C) the mTORC1 inhibitor Rapamycin or vehicle control (0.1% DMSO) followed by heat stress (45°C) or control (37°C) for 10 minutes were plated in soft-agar and colonies of 50 or more cells were counted 14 days after plating using a light microscope. Percent colony formation per cell number plated was calculated and the data normalized to the non-heat stressed, 37°C control to calculate percent colony formation relative control to 37°C control. Data are presented as mean±SEM of 3 independent experiments (One-way ANOVA followed by post-hoc pairwise comparison using an unpaired t-test). ns P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001

S11 Fig. Isoform-specific expression of AKT in rat and human HCC cells. Whole cell lysates were prepared from N1S1 and AS30D rat HCC cells and Hep3B and HuH7 human HCC cells and were subjected to western immunoblotting for AKT1, AKT2, AKT3 and total AKT. β-actin was used as a loading control.

S1 Table. Doubling time and metabolic activity of Clone9 rat hepatocyte and N1S1 and AS30D rat HCC cell lines in vitro.

S2 Table. Top Biological Functions: HCC v. Hepatocyte (Ingenuity Pathway Analysis).

S3 Table. Top Canonical Pathways: HCC v. Hepatocyte (Ingenuity Pathway Analysis).

S4 Table. Top Transcription Factors: HCC v. Hepatocyte (Ingenuity Pathway Analysis).

S5 Table. Top Up- and Down-Regulated Molecules: HCC v. Hepatocyte (Ingenuity Pathway Analysis).

S6 Table. In vitro and in vivo characteristics of Clone 9 hepatocyte and N1S1 and AS30D HCC model system.

S1 File. Whole transcriptome gene expression data for the N1S1 HCC versus Clone 9 hepatocyte cell lines.

S2 File. Whole transcriptome gene expression data for the AS30D HCC versus Clone 9 hepatocyte cell lines.

S3 File. Supplemental Methods.

Acknowledgments
We would like to thank the Mayo Clinic Medical Genome Facility (MCF) Gene Expression and Bioinformatics Cores for their assistance with the whole transcriptome microarray analyses in the rat hepatocyte and HCC cell lines and the proteomics group at Cell Signaling Technology.
for their assistance with performing the Kinomeview® analyses. Dr. Thompson thanks the Mayo Clinic Medical Scientist Training Program (MSTP) for fostering an outstanding environment for physician-scientist training.

**Author Contributions**

**Conceptualization:** SMT MRC DEJ KAB BEK JLA SLS JL JPG LRR DAW.

**Formal analysis:** SMT MRC DEJ JL JPG LRR DAW.

**Funding acquisition:** SMT LRR DAW.

**Investigation:** SMT MRC DEJ KAB BEK JLA KL SLS JL JPG LRR DAW.

**Methodology:** SMT MRC DEJ KAB BEK JLA SLS JL SST JPG LRR DAW.

**Project administration:** SMT MRC DEJ KAB BEK JLA JPG LRR DAW.

**Resources:** SMT MRC JL SST JPG LRR DAW.

**Supervision:** SMT MRC DEJ JPG LRR DAW.

**Validation:** SMT MRC DEJ JPG LRR DAW.

**Visualization:** SMT MRC DEJ JL JPG LRR DAW.

**Writing – original draft:** SMT DEJ DAW.

**Writing – review & editing:** SMT MRC DEJ KAB BEK JLA SLS JPG LRR DAW.

**References**

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359–86. doi: 10.1002/ijc.29210 PMID: 25220842

2. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63(5):844–55. doi: 10.1136/gutjnl-2013-306627 PMID: 24531850

3. Yang JD, Kim B, Sanderson SO, St Sauver JL, Yawn BP, Pedersen RA, et al. Hepatocellular carcinoma in Olmsted county, Minnesota, 1976–2008. Mayo Clin Proc. 2012; 87(1):9–16. doi: 10.1016/j.mayocp.2011.07.001 PMID: 22212963

4. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010; 7(8):448–58. doi: 10.1038/nrgastro.2010.100 PMID: 20628345

5. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology. 2009; 136(4):1134–44. doi: 10.1053/j.gastro.2009.02.038 PMID: 19245868

6. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011; 98(9):1210–24. doi: 10.1002/bjs.7669 PMID: 21766289

7. Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012; 56(2):412–8. doi: 10.1016/j.jhep.2011.05.020 PMID: 21756858

8. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009; 49(2):453–9. doi: 10.1002/hep.22648 PMID: 19065676

9. Yin XY, Xie XY, Lu MD, Xu HX, Xu ZF, Kuang M, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer. 2009; 115(9):1914–23. doi: 10.1002/cncr.24196 PMID: 19241423

10. Kao WY, Chiou YY, Hung HH, Chou YH, Su CW, Wu JC, et al. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index. Eur J Gastroenterol Hepatol. 2011; 23(6):528–36. doi: 10.1097/MEG.0b013e282436d529 PMID: 21537128
11. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg. 2008; 12(1):183–91. PMID: 17874276

12. Yang B, Zou J, Xia J, Ren Z, Gan Y, Wang Y, et al. Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous radiofrequency ablation. Eur J Radiol. 2011; 79(2):196–200. doi: 10.1016/j.ejrad.2010.02.010 PMID: 20303686

13. Angone C, Baldan A, Cillo U, D’Alessandro A, De Antoni M, De Giorgio M, et al. Complications of radiofrequency thermal ablation in hepatocellular carcinoma: what about "explosive" spread? Gut. 2006; 55(3):435–6. PMID: 16474113

14. Portolani N, Tiberio GA, Ronconi M, Coniglio A, Ghidoni S, Gaverini G, et al. Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology. 2003; 50(54):2179–84. PMID: 14696492

15. Ruussenente A, Manzoni GD, Molfetta P, Gencer B, Donattaccio M, et al. Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation. World J Gastroenterol. 2003; 10(8):1137–40. PMID: 15069713

16. Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, et al. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol. 2001; 13(3):291–4. PMID: 11293452

17. Shiozawa K, Watanabe M, Takahashi M, Waku N, Iida K, Sumino Y. Analysis of patients with rapid aggressive tumor progression of hepatocellular carcinoma after percutaneous radiofrequency ablation. Hepatogastroenterology. 2009; 56(96):1689–95. PMID: 20214219

18. Kang TW, Lim HK, Lee MW, Kim YS, Rhim H, Lee WJ, et al. Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance. Radiology. 2015:141215.

19. Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg. 2003; 197(5):759–64. PMID: 14585410

20. Kei SK, Rhim H, Choi D, Lee WJ, Lim HK, Kim YS. Local tumor progression after radiofrequency ablation of liver tumors: analysis of morphologic pattern and site of recurrence. AJR Am J Roentgenol. 2008; 190(6):1544–51. doi: 10.2214/AJR.07.2798 PMID: 18492905

21. Liu CH, Arellano RS, Uppot RN, Samir AE, Gervais DA, Mueller PR. Radiofrequency ablation of hepatic tumours: effect of post-ablation margin on local tumour progression. Eur Radiol. 2010; 20(4):877–85. doi: 10.1007/s00330-009-1610-4 PMID: 19760232

22. Mertyna P, Dewhirst MW, Halpern E, Goldberg W, Goldberg SN. Radiofrequency ablation: the effect of distance and baseline temperature on thermal dose required for coagulation. Int J Hyperthermia. 2008; 24(7):550–9. doi: 10.1080/02656730802035662 PMID: 18608586

23. Mertyna P, Hines-Peralta A, Liu ZJ, Halpern E, Goldberg W, Goldberg SN. Radiofrequency ablation: variability in heat sensitivity in tumors and tissues. J Vasc Interv Radiol. 2007; 18(5):647–54. PMID: 17494847

24. Thompson SM, Callstrom MR, Butters KA, Knudsen B, Grande JP, Roberts LR, et al. Heat stress induced cell death mechanisms in hepatocytes and hepatocellular carcinoma: in vitro and in vivo study. Lasers Surg Med. 2014; 46(4):290–301. doi: 10.1002/lsm.22231 PMID: 24643941

25. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivas G, Kernier T, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002; 43(1):33–56. PMID: 12098606

26. Park HG, Han SI, Oh SY, Kang HS. Cellular responses to mild heat stress. Cell Mol Life Sci. 2005; 62(1):10–23. PMID: 15619003

27. Ahmed M, Goldberg SN. Basic science research in thermal ablation. Surg Oncol Clin N Am. 2011; 20(2):237–58, vii. doi: 10.1016/j.soc.2010.11.011 PMID: 21377581

28. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Miguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis. 2010; 30(1):35–51. doi: 10.1055/s-0030-1247131 PMID: 20175032

29. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006; 12(4):410–6. PMID: 16532004

30. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010; 29(36):4989–5005. doi: 10.1038/onc.2010.236 PMID: 20639898
31. Dhanasekaran R, Venkatesh SK, Torbenson M, Roberts LR. Clinical Implications of Basic Research in Hepatocellular Carcinoma. J Hepatol. 2016; 64(3):736–45. doi: 10.1016/j.jhep.2015.09.008 PMID: 26450813

32. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004; 40(3):667–76. PMID: 15349906

33. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004; 36(12):1306–11. PMID: 15565109

34. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology. 2008; 47(4):1211–22. doi: 10.1002/hep.22202 PMID: 18318435

35. Zheng X, Vittar NB, Gai X, Fernandez-Barrera MG, Moser CD, Hu C, et al. The transcription factor GLI1 mediates TGFbeta1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism. PLoS One. 2012; 7(11):e49581. doi: 10.1371/journal.pone.0049581 PMID: 23185371

36. Minko T, Kopeckova P, Kopecek J. Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J Control Release. 1999; 59(2):133–48. PMID: 10332049

37. Thompson SM, Callstrom MR, Butters KA, Sutor SL, Knudsen B, Grande JP, et al. Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation: in vitro and in vivo pilot study. Cardiovasc Intervent Radiol. 2014; 37(5):1343–51. doi: 10.1007/s00270-013-0828-3 PMID: 24452318

38. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol. 2005; 23(1):94–101. PMID: 15592455

39. Thompson SM, Callstrom MR, Knudsen B, Anderson JL, Carter RE, Grande JP, et al. Development and Preliminary Testing of a Translational Model of Hepatocellular Carcinoma for MR Imaging and Interventional Oncologic Investigations. J Vasc Interv Radiol. 2012; 23(3):385–95. doi: 10.1016/j.jvir.2011.11.018 PMID: 22265247

40. Thompson SM, Callstrom MR, Knudsen BE, Anderson JL, Butters KA, Grande JP, et al. Molecular Bioluminescence Imaging as a Noninvasive Tool for Monitoring Tumor Growth and Therapeutic Response to MRI-Guided Laser Ablation in a Rat Model of Hepatocellular Carcinoma. Invest Radiol. 2013; 48(6):413–21. doi: 10.1097/RLI.0b013e31827e4a3f PMID: 22923329

41. Thompson SM, Callstrom MR, Knudsen B, Anderson JL, Butters KA, Grande JP, et al. AS30D Model of Hepatocellular Carcinoma: Tumorigenicity and Preliminary Characterization by Imaging, Histopathology, and Immunohistochemistry. Cardiovasc Intervent Radiol. 2013; 36(1):198–203. doi: 10.1007/s00270-013-0671-3 PMID: 22923329

42. Joshi CN, Jain SK, Murthy PS. An optimized triphenyltetrazolium chloride method for identification of cerebral infarcts. Brain Res Brain Res Protoc. 2004; 13(1):11–7. PMID: 15063836

43. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984; 10(6):787–800. PMID: 6547421

44. Zhang BH, Guan KL. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. Embo J. 2000; 19(20):5429–39. PMID: 11032810

45. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26(22):3291–310. PMID: 17496923

46. Klippel A, Kavanaught WM, Pot D, Williams LT. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol. 1997; 17(1):338–44. PMID: 8972214

47. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307(5712):1098–101. PMID: 15718470

48. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7):1261–74. PMID: 17604717

49. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005; 24(50):7455–64. PMID: 16288292

50. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis. 2005; 25(2):212–25. PMID: 15918149

51. Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol. 2011; 7(10):1149–67. doi: 10.2217/fon.11.95 PMID: 21992728
52. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer. 2005; 103(2):307–12. PMID: 15593087

53. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006; 25(27):3787–800. PMID: 16799620

54. Schmitz KJ, Wohlschlaeger J, Lang H, Sotropoulos GC, Malago M, Steveling K, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008; 48(1):83–90. PMID: 17998146

55. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997; 91(2):231–41. PMID: 9346240

56. Cross DA, Alessi DR, Cohen P, Andjelkovic M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378(6559):785–9. PMID: 8524413

57. Zhang Y, Gan B, Liu D, Paik JH. FoxO family members in cancer. Cancer Biol Ther. 2011; 12(4):253–9. PMID: 21613825

58. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008; 7(7):1851–63. doi: 10.1158/1535-7163.MCT-08-0017 PMID: 18606717

59. Huynh H, Soo KC, Chow PK, Tran E. Targeted inhibition of the extracellular signal-regulated kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther. 2007; 6(1):138–46. PMID: 17237274

60. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149(2):274–93. doi: 10.1016/j.cell.2012.03.017 PMID: 22500797

61. Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res. 2012; 18(19):5290–303. doi: 10.1158/1078-0432.CCR-12-0563 PMID: 22872574

62. Shaw M, Cohen P, Alessi DR. The activation of protein kinase B by H2O2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-activated protein kinase-activated protein kinase-2. Biochem J. 1998; 336 (Pt 1):241–6. PMID: 9806907

63. Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, et al. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Anticancer Research. 2012; 32 (7):2531–6. PMID: 22753710

64. Koseoglu S, Lu Z, Kumar C, Kirschmeier P, Zou J. AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines. Cancer Biol Ther. 2007; (5):755–62. PMID: 17426444
73. Hara S, Nakashiro K, Goda H, Hamakawa H. Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. Biochem Biophys Res Commun. 2008; 370(1):123–8. doi: 10.1016/j.bbrc.2008.03.042 PMID: 18355439

74. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle. 2009; 8(16):2502–8. PMID: 19597332

75. Sasaki T, Nakashiro K, Tanaka H, Azuma K, Goda H, Hara S, et al. Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. Biochem Biophys Res Commun. 2010; 399(1):79–83. doi: 10.1016/j.bbrc.2010.07.045 PMID: 20638364